Cioteronel

Cioteronel
Clinical data
Other namesCPC-10997; Cyoctol; X-Andron
Routes of
administration		By mouth, topical
Drug classNonsteroidal antiandrogen
ATC code
  • None
Identifiers
IUPAC name
  • 4-(5-methoxyheptyl)-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H28O2
Molar mass252.398 g·mol−1
3D model (JSmol)
SMILES
  • CCC(CCCCC1CCC2C1CC(=O)C2)OC
InChI
  • InChI=InChI=1S/C16H28O2/c1-3-15(18-2)7-5-4-6-12-8-9-13-10-14(17)11-16(12)13/h12-13,15-16H,3-11H2,1-2H3
  • Key:KDULJHFMZBRAHO-UHFFFAOYSA-N

Cioteronel (INN, USAN) (developmental code name CPC-10997; former tentative brand names Cyoctol, X-Andron) is a nonsteroidal antiandrogen (NSAA) that was never marketed.[1][2][3] It was under development between 1989 and 2001 for the topical treatment of androgenetic alopecia (male pattern baldness) and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.[3][4]

See also

References

  1. ↑ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. p. 570. ISBN 978-0-412-46630-4.
  2. ↑ Lednicer D (21 November 1994). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 11–. ISBN 978-0-471-58959-4.
  3. 1 2 Tiwari A, Krishna NS, Nanda K, Chugh A (November 2005). "Benign prostatic hyperplasia: an insight into current investigational medical therapies". Expert Opinion on Investigational Drugs. 14 (11): 1359–72. doi:10.1517/13543784.14.11.1359. PMID 16255676. S2CID 25662071.
  4. ↑ "Cioteronel". Adis Insight. Springer Nature Switzerland AG. Archived from the original on 2016-12-29. Retrieved 2016-11-25.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.